Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285070 · ClinicalTrials.gov registry record · Phase 2
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
A Phase 2 study, sponsored by Novaliq.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07285070: Recruiting Phase 2 study, sponsored by Novaliq.
NCT07285070 is a Phase 2 study that is actively recruiting participants, run by Novaliq. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07285070, a Phase 2 study, is actively recruiting participants, sponsored by Novaliq.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
Primary Outcome
ocular and non-ocular adverse events
Interventions
- DRUG Tacrolimus ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What NCT07285070 shows while recruiting
NCT07285070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus ophthalmic solution is the first listed.
NCT07285070 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07285070 about?
NCT07285070 is a clinical study titled "Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis". The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
What is the current status of trial NCT07285070?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-03-16. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07285070?
The interventions under investigation include: Tacrolimus ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT07285070?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07285070's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI